163 related articles for article (PubMed ID: 37312213)
21. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
Harrow S; Palma DA; Olson R; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):611-616. PubMed ID: 35643253
[TBL] [Abstract][Full Text] [Related]
22. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma.
Koong AJ; Toesca DAS; Baclay JRM; Pollom EL; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2020; 10(4):274-281. PubMed ID: 32119922
[TBL] [Abstract][Full Text] [Related]
23. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
Holyoake DL; Ward E; Grose D; McIntosh D; Sebag-Montefiore D; Radhakrishna G; Patel N; Silva M; Mukherjee S; Strauss VY; Odondi L; Fokas E; Melcher A; Hawkins MA
BMC Cancer; 2016 Sep; 16(1):728. PubMed ID: 27619800
[TBL] [Abstract][Full Text] [Related]
24. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
26. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
Simoni N; Micera R; Rossi G; Giri MG; Pavarana M; Muraglia A; Cernusco NLV; DE Liguoro M; Guariglia S; Cavedon C; Milella M; Mazzarotto R
Anticancer Res; 2020 Oct; 40(10):5901-5907. PubMed ID: 32988921
[TBL] [Abstract][Full Text] [Related]
29. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes.
Elamir AM; Karalis JD; Sanford NN; Polanco PM; Folkert MR; Porembka MR; Kazmi SA; Maddipati R; Zeh HJ; Timmerman RD; Zhang S; Ligorio M; Beg MS; Aguilera TA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):792-802. PubMed ID: 35896145
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
32. Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
Chi A; Wen S; Monga M; Almubarak M; He X; Rojanasakul Y; Tse W; Remick SC
PLoS One; 2016; 11(9):e0162453. PubMed ID: 27611833
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
34. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
35. Metastatic pulmonary adenocarcinoma 6 years after curative resection for ampullary adenocarcinoma. Metastatic disease from initial primary or metachronous tumour?
Giakoustidis A; Cherian PT; Zen Y; Jassem W; Prachalias A; Srinivasan P; Heaton ND; Rela M
JOP; 2011 Jan; 12(1):32-6. PubMed ID: 21206098
[TBL] [Abstract][Full Text] [Related]
36. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
[TBL] [Abstract][Full Text] [Related]
38. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy for early stage lung cancer and lung metastases in a New Zealand population.
Geary RL; Yasin NABH; Lin F; Whalley D; Thotathil Z; De Groot C
N Z Med J; 2021 Feb; 134(1529):45-56. PubMed ID: 33582707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
